Research programme: histone and peptide based therapeutics - SymbioTec

Drug Profile

Research programme: histone and peptide based therapeutics - SymbioTec

Alternative Names: rhH1 x; rhH1.x

Latest Information Update: 25 Jan 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SymbioTec
  • Class Peptides; Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jan 2012 SymbioTec has been acquired by Xenetic Biosciences
  • 09 Jul 2010 No development reported - Preclinical for Cancer in Germany (unspecified route)
  • 24 Apr 2007 Preclinical trials in Acute myeloid leukaemia in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top